Cure8 research brief
The review highlights how microbial metabolites, epigenetic regulation, and mitochondrial metabolism interact to shape inflammation and barrier function in IBD. Understanding these links could help identify new biomarkers and therapeutic targets.
Researchers, clinicians, and adult patients interested in IBD mechanisms, microbiome research, and biomarker-driven or precision therapies.
The article synthesizes research linking gut microbial changes (loss of short-chain fatty acid producers, expansion of pro-inflammatory taxa) to shifts in host chromatin states via microbial metabolites such as SCFAs, secondary bile acids, and tryptophan-derived products.
Epigenetic changes in epithelial and immune cells are discussed as mediators that can reinforce dysbiosis and chronic inflammation. The authors propose a conceptual "microbiome–epigenome–mitochondrial" axis that could guide biomarker discovery and development of therapies that target microbiota or epigenetic pathways.
The review is a synthesis of emerging studies rather than a report of a single clinical trial; it highlights potential translational paths (epigenetic modulators, microbiota-targeted interventions) but does not present new trial results or treatment recommendations.
This is a review article (abstract summarized here) synthesizing recent studies; it proposes a conceptual framework but does not report new clinical trial results. Findings discussed are at varied stages of research translation.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study synthesizes many stool metagenomes to find consistent microbial species, functional pathways, and strain-level differences linked to IBD and to distinctions between Crohn’s disease and ulcerative...
This review spotlights non-bacterial members of the gut microbiota (viruses and fungi) that may contribute to IBD by altering barrier function, immune responses, and interactions with bacteria. For people with IBD, these...
This study suggests machine learning of stool microbiome data could eventually help distinguish IBD (especially Crohn’s) from healthy people and some other bowel or systemic conditions.
